Research into bowel (colorectal) cancer

Researchers around the world are looking at the causes, diagnosis and treatment of bowel cancer.

All cancer treatments must be fully researched before they can be used for everyone. This is so we can be sure that:

  • they work
  •  they work better than the treatments already available
  • they are safe

Go to Cancer Research UK’s clinical trials database if you are looking for a trial for bowel cancer in the UK. You need to talk to your specialist if there are any trials that you think you might be able to take part in.

Research into genes and bowel cancer

The risk of developing bowel cancer is higher in people who have a family history of bowel cancer. This can be caused by an inherited gene change. The risk increases depending on which gene is damaged or which part of the gene is damaged.

Researchers are learning more about genes and gene faults linked to bowel cancer. They are looking at blood and tissue samples from people who have had bowel cancer, as well as blood samples from people who haven't had cancer. They are also collecting information about family history.

Research into diet and exercise

We know that eating a high fibre diet, less red meat and processed meat can reduce the risk of bowel cancer. There is also strong evidence that a healthy weight and exercising lowers the risk of bowel cancer.

Researchers are looking at exercise programmes. They want to find out if following an exercise programme before and after bowel surgery, will help improve your recovery.

Research into aspirin and bowel cancer

Researchers are looking into whether drugs can prevent bowel cancer. They have looked at non steriodal anti inflammatory drugs (NSAIDS) such as aspirin to see if they can prevent bowel cancer developing. Results suggest that aspirin might reduce the risk of bowel cancer developing.

They are also looking into how aspirin affects cancer spread and whether it can stop cancer coming back after treatment.

Research into surgery for rectal cancer

A serious possible side effect of rectal cancer surgery is a leak from where 2 bits of bowel have been joined. This is called an anastomotic leak.

A research study wants to see if a new technology can help reduce this. They want to use a technology called Intraoperative Fluorescence Angiography (IFA) during the operation. This is a dye which is injected into the blood and makes it glow. It shows the surgeons the blood supply around the join which can help them make decisions during the operation.

Research into treatment for bowel cancer

Trials are looking at different chemotherapy drugs, either on their own or with other treatments such as targeted drugs and immunotherapy.

Targeted cancer drugs change the way cells work. They can block the signals that tell cells to grow. Immunotherapies can boost the body’s immune system to fight off or kill cancer cells.

Researchers are looking at giving these drugs on their own or with chemotherapy. So far this is mainly for advanced bowel cancer.

There are many types of targeted drugs and immunotherapies. For bowel cancer, researchers are looking at:

  • drugs that block cancer blood vessel growth (anti angiogenesis treatment), such as aflibercept and lenvatinib
  • monoclonal antibodies, such as panitumumab
  • immunotherapies, such as pembrolizumab, durvalumab
  • a new virus treatment for rectal cancer called enadenotucirev (EnAd)
  • Clinical trials database
    Cancer Research UK
    Accessed February 2022

  • Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy
    National Institute for Health and Care Excellence (NICE) Guidelines, 2012 (updated 2015)

  • Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    G Argilés and others
    Annals of Oncology, 2020. Volume 31, Issue 10 Pages 1291-1305

  • ESMO consenus guidelines for the management of patients with metastatic colorectal cancer
    E Van Custem and others
    Annals of Oncology 27: 1386 - 1422, 2016

  • Offer daily aspirin to those with inherited genetic condition to reduce the risk of colorectal cancer
    National Institute for Health and Care Excellence (NICE)
    Accessed February 2022

  • Systemic therapy for colorectal cancer
    JA Meyerhardt and others
    New England Journal of Medicine 2005 V352 (5)

Last reviewed: 
08 Feb 2022
Next review due: 
08 Feb 2025

Related links